



Small but heading for the big time

Nanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3

Paris, Cambridge, January 5, 2016 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today that, in addition to its current advanced clinical development program, the Company has started exploring the use of NBTXR3 for combination in Immuno Oncology.

Elsa Borghi, Nanobiotix's Medical Director, commented: *"With six ongoing indications, our global clinical development of NBTXR3 as a radio-enhancer, is progressing well. This Immuno Oncology program could bring new applications and confirm that additional patient populations could benefit from treatment with NBTXR3"*.

NBTXR3 current clinical development

NBTXR3 is a radio-enhancer, using a physical mode of action to destroy cancer cells in any solid tumors, in combination with radiotherapy.

Nanobiotix is running a global clinical development program with its lead product NBTXR3, in six indications across Europe, the US and the Asia-Pacific Region: a registration trial in soft tissue sarcoma, and Phase I/II trials in liver cancers (HCC and liver metastases), prostate cancer, head and neck cancer and rectal cancer (in Asia by Nanobiotix's partner PharmaEngine).

In situ (intratumoral) vaccination with NBTXR3 opens new potential prospects in Immuno Oncology

The aim of Immuno Oncology (IO) is to boost patients' immune systems to fight cancer, through different approaches. It is very efficient for a limited number of patients whose tumors have natural and sufficient immunogenicity. However, to exploit the full potential of immune therapies it is necessary to increase this immunogenicity at tumor level.

Indeed, it has been demonstrated that radiotherapy can be used to improve immunogenicity, by creating Immunogenic Cell Death (ICD) in many situations.

NBTXR3 nanoparticles' activation enhances the energy deposited where they are injected, improving the cancer cell death and efficacy of radiotherapy. This technology is based on physics and can potentially be applied across all radiotherapy indications. All preclinical model have shown a systematic superiority of cell killing, when using NBTXR3 with radiotherapy, compared to radiotherapy alone.

Hence, NBTXR3 could have the potential to be used as an in situ (intratumoral) vaccination that would create ICDs which, in turn, could bring a new dimension and broaden the usage of immuno therapies in oncology.

To explore this brand new field of development opportunities, the Company has launched a pre-clinical development program.

-Ends-

About NANObIOTIX: www.nanobiotix.com

Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company's first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy with a view to provide a new, more efficient treatment for cancer patients.

NanoXray products are compatible with current radiotherapy treatments and are meant to treat potentially a wide variety of solid tumors including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, glioblastoma, etc., via multiple routes of administration.

Nanobiotix's lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma, head and neck Cancer, prostate cancer, rectal cancer (PharmaEngine) and liver cancers (HCC and liver metastases). The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia.

Nanobiotix is listed on the regulated market of Euronext in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO:FP). The Company Headquarter is based in Paris, France. Affiliate in Cambridge, United States.

Contact

Nanobiotix

Sarah Gaubert
Head of Communication and Public Affairs
+33 (0)1 40 26 07 55
contact@nanobiotix.com



Media relations

France - NewCap
Annie-Florence Loyer
+33 (0)6 88 20 35 59
afloyer@newcap.fr

Outside France - **Instinctif Partners**
Melanie Toyne Sewell
+44 (0) 207 457 2020
nanobiotix@instinctif.com

Disclaimer

This press release contains certain forward-looking statements concerning Nanobiotix and its business. Such forward-looking statements are based on assumptions that Nanobiotix considers to be reasonable. However, there can be no assurance that the estimates contained in such forward-looking statements will be verified, which estimates are subject to numerous risks including the risks set forth in the 2014 annual financial report of Nanobiotix (a copy of which is available on www.nanobiotix.com) and to the development of economic conditions, financial markets and the markets in which Nanobiotix operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Nanobiotix or not currently considered material by Nanobiotix. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Nanobiotix to be materially different from such forward-looking statements.

This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Nanobiotix shares in any country.